Amarin Corp plc

A US appeals court decision to revive litigation between Amarin and Hikma , in which the originator is claiming induced infringement of Vascepa (icosapent ethyl) by Hikma’s generic version, “makes

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Cycle Offers $466m For Vanda, Which Tur

Imperative And Execution At the end of May 2024, the NASDAQ Biotech Index (NBI) fell into negative territory both in the year to date and compared with the previous 12 months. This was despite the imp

Better In Big Pharma? I listened to a discussion recently on the discount rates used to value pharmaceutical and biotechnology products. One of the speakers suggested that the same asset should have a